BELOIT, Wis., Feb. 21, 2011 /PRNewswire/ — Sheffield
Bio-Science, a Kerry Group Business, has formed a strategic global
sales, marketing and development alliance with Wockhardt Ltd. Under
this partnership, Sheffield Bio-Science will be the Exclusive
Global Sales and Distribution Partner for recombinant insulin
manufactured by global Indian biotech Wockhardt. According to
estimates, the potential in cell culture markets is around US$ 50
million.
Speaking on this landmark alliance, Dr. Habil Khorakiwala,
Chairman, Wockhardt Group stated, “This partnership is a
reaffirmation of Wockhardt’s biotechnology research prowess and a
confluence of innovative novel technology now being offered to
global cell culture markets.”
Sheffield’s Director of Global Business Development, Hans
Huttinga, stated, “We are looking forward to developing a strong
and lasting partnership between our organizations.”
Wockhardt was the first in Asia and only the fourth company in
the world to have developed, manufactured and marketed Wosulin
– recombinant insulin injectables. Wockhardt’s
state-of-the-art Biotech Park in Aurangabad has six dedicated
manufacturing facilities and was inaugurated by the then President
of India, His Excellency, Dr. APJ Abdul Kalam.
“This strategic alliance marks another step in our continued
investment to strengthen our cell culture media supplement
portfolio,” said Edmond Scanlon, President of Sheffield
Bio-Science.
Sheffield Bio-Science continues its evolution to deliver a
complete novel technology platform to the global cell culture
market. Customers will now have greater access to the industry’s
most innovative and extensive cell culture media
ingredient-technologies, including recombinant proteins, chemically
defined metabolic enhancers, hydrolyzed proteins, and yeast
extracts. Such high quality solutions make it easier for
biopharmaceutical manufacturers to delay apoptosis and maximize
product yields.
About Sh
‘/>”/>
